Clinical Trial Detail

NCT ID NCT03488225
Title Hyper-CVAD in Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With Acute Lymphocytic Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors M.D. Anderson Cancer Center
Indications

acute lymphocytic leukemia

Therapies

Mercaptopurine + Methotrexate + Prednisone + Vincristine

Cytarabine + Leucovorin + Methotrexate

inotuzumab ozogamicin

Ofatumumab

Rituximab

Cytarabine + Doxorubicin + Methotrexate + Vincristine

Pegfilgrastim

Cyclophosphamide + Dexamethasone + Mesna

Age Groups: child adult

Additional content available in CKB BOOST